Lantern Pharma (LTRN) Stock Analysis & Winston Score

Lantern Pharma is a small biotech company that uses artificial intelligence to help develop cancer drugs. It takes existing drug compounds — many of which were previously abandoned by larger companies — and uses its AI platform, called RADR, to figure out which patients are most likely to respond to those drugs. Its main focus is oncology, meaning all of its work targets different types of cancer. The company does not yet sell any approved products, so it currently earns no meaningful revenue. It is based in Dallas, Texas, and operates primarily in the United States, though its drug development work involves clinical trials that can span multiple sites. Its competitive angle is the RADR platform, which it argues can reduce the cost and time of drug development by predicting patient outcomes using genomic data. The key risk is that the company is pre-revenue, burns cash consistently, and depends entirely on its pipeline drugs successfully completing clinical trials and eventually gaining regulatory approval.